CTL 68H7-819 targets the leukemic stem cell in T-lymphoid blast phase CML (CML-BC). (A) Recognition of CML-BC cells by CTL 68H7-819 in a 51Cr release assay at the indicated E/T ratios. (B) Survival analysis of mice injected with CML-BC cells cultured overnight in medium alone or with CTL 68H7-819. Each group was composed of 5 mice. (C) Flow cytometric analysis using human PE-conjugated antihuman CD34 and FITC-conjugated anti–HLA-B27 antibodies of BMMCs from representative mice injected with CML-BC cells that had been cultured overnight in medium alone or with CTL 68H7-819. Uninjected CML-BC cells were used as a positive control. (D) Human Y-chromosome PCR analysis of genomic DNA extracted from mouse BMMCs to detect human male leukemic cells. Flow cytometric and PCR analysis was performed on mice that survived at least 15 days after injection.
